This is a working overview of half-life, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-22. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
== History == Prostaglandin H2 was discovered in 1973 by Diederik H. Nugteren and Elly Christ-Hazelhof while they were researching the formation of prostaglandin E2 from arachidonic acid using enzymes found in vesicular glands.
apical constriction The process by which contraction of the apical side of a cell (and often a corresponding expansion of the opposing basal side) causes the cell to assume a wedge-shaped morphology. The process is common during early development, where it is often coordinated across many adjacent cells of an epithelial layer simultaneously in order to generate bends or folds in developing tissues.
=== Signaling === D-Serine, synthesized in neurons by serine racemase from L-serine (its enantiomer), serves as a neuromodulator by coactivating NMDA receptors, making them able to open if they then also bind glutamate. D-serine is a potent agonist at the glycine site (NR1) of canonical diheteromeric NMDA receptors. For the receptor to open, glutamate and either glycine or D-serine must bind to it; in addition a pore blocker must not be bound (e.g. Mg2+ or Zn2+). Some research has shown that D-serine is a more potent agonist at the NMDAR glycine site than glycine itself. However, D-serine has been shown to work as an antagonist/inverse co-agonist of t-NMDA receptors through the glycine binding site on the GluN3 subunit.
In February 1983 he fell over in the melée (he said at the time that he was pushed) when CND protestors surrounded a meeting of Newbury Conservatives, a propaganda gift, and on Good Friday 1983 he was filmed in West Berlin looking over the wall to the communist east, distracting attention from CND's linking of arms round Greenham Common that day. With a general election looming, Heseltine was keen to associate Labour with CND, and CND with communists and the Soviet Union (ignoring earlier comments by Party Chairman Cecil Parkinson that this was "manifest nonsense" – the media did not pick up on this). He made such a claim in a speech at Exeter in April 1983, and distributed to Tory candidates information about the background of leading members of CND. This had been assembled by Ray Whitney MP, but some of it was suspected of having come from intelligence sources. MI5 agent Cathy Massiter later wrote, in 1985 in The Observer, that from 1981 onwards and especially from 1983 she had been asked to pass on to DS19 (the propaganda unit at the Ministry of Defence) information obtained by wiretaps and by an MI5 mole in CID. MI5 bosses refused to pass on classified material about security matters but agreed to pass on information about the political links of CND members. Even this was in breach of the 1952 Directive from Home Secretary David Maxwell-Fyfe that the security services not provide information for party political purposes.
Sources: en.wikipedia.org
Border security and immigration were among the top issues concerning potential voters in the election. Polling showed that most Americans want to reduce immigration, and that a substantial minority of white Republicans were concerned about white demographic decline. In 2023 and early 2024, a surge of migrants entering through the border with Mexico occurred. By June 2024, illegal crossings reached a three-year low following four consecutive monthly drops, which senior officials attributed to increased enforcement between the United States and Mexico, the weather, and Biden's executive order (A Proclamation on Securing the Border) increasing asylum restrictions. Harris promised to fight for "strong border security" coupled with an earned pathway to citizenship. Harris highlighted her work in combating transnational gangs, drug cartels, and human traffickers while attorney general. As vice president, Harris announced in 2023 that she had garnered pledges of US$950 million from private companies to aid Central American communities to address the causes of mass migration, such as poverty. Harris stated she believes the immigration system is "broken" and needs to be fixed, and she said most Americans believe this. Harris also advocated for stricter asylum rules than Biden. Harris supported increasing the number of U.S. Border Patrol agents and accused Trump of being unserious on border security. As vice president, Harris also supported a bipartisan bill that would have funded additional border agents and closed the border if too crowded; the bill was rejected by Trump.
The PLA Ground Force (PLAGF) is the largest of the PLA's five services with 960,000 active duty personnel, approximately half of the PLA's total manpower of around 2 million personnel. The PLAGF is organized into twelve active duty group armies sequentially numbered from the 71st Group Army to the 83rd Group Army which are distributed to each of the PRC's five theatre commands, receiving two to three group armies per command. In wartime, numerous PLAGF reserve and paramilitary units may be mobilized to augment these active group armies. The PLAGF reserve component comprises approximately 510,000 personnel divided into thirty infantry and twelve anti-aircraft artillery (AAA) divisions. The PLAGF is led by Commander Li Qiaoming and Political Commissar Chen Hui (general).
=== Pest risk analysis === As of 2019 the East African Community considers P. aeruginosa to be a quarantine concern because of the presence of Phaseolus vulgaris–pathogenic strains of P. aeruginosa in Kenya for the rest of the area. A pest risk analysis by the EAC was based on this bacterium's CABI's Crop Protection Compendium listing, following Kaaya & Darji 1989's initial detection in Kenya.
In vitro studies indicate gepotidacin can inhibit specific drug transporters, but the clinical significance of these findings requires further evaluation. Excretion is mainly fecal (~52%, 30% unchanged) and urinary (~31%, 20% unchanged), with the latter being the major route for absorbed drug. Renal impairment leads to elevated gepotidacin exposure, with the degree of increase directly linked to the severity of kidney dysfunction. This effect is particularly pronounced in patients with end-stage renal disease undergoing hemodialysis. Additionally, impaired kidney function decreases urinary excretion of the drug, which may necessitate dosage adjustments in severe cases to ensure safe and effective treatment. Severe hepatic impairment also elevates gepotidacin exposure, while moderate hepatic impairment did not show a clinically relevant effect during clinical trials.
, gives an indication of how incompatible the two blocks are and whether they will microphase separate. For example, a diblock copolymer of symmetric composition will microphase separate if the product
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.